Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies GENOA, Italy, December 1, 2023 — IAMA Therapeutics, a pharmaceutical company focused […]

GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]

GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]